Veramorph is a specialty pharma company with a differentiated platform oral dosage technology. We are growing a pipeline of unique orally reformulated generic drugs and new molecular entity co-development partnerships to generate revenue from a risk-averse blend of licensing agreements with commercialization partners. Doug, founder and CEO, invented the technology as an MIT postdoc and has 10 years experience in formulations. Acting VP of manufacturing, Colin Minchom, has over 30 years of drug product experience. Leadership is complemented by a team of consultants covering legal, regulatory, and pre-clinical topics and guided by an advisory board of several experienced entrepreneurs. $675K raised (11.2022). (Update - $225,000 NSF SBIR Phase 1.
